Senti Biosciences Holdings (SNTI) Return on Capital Employed (2021 - 2025)
Senti Biosciences Holdings (SNTI) recorded quarterly Return on Capital Employed of 181.09% in Q4 2025, down 32.69% quarter-over-quarter from 136.48% in Q3 2025, and down 8666.0% on a YoY basis from 2.11% in Q4 2024.
Senti Biosciences Holdings (SNTI) Return on Capital Employed (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Return on Capital Employed history runs 5 years deep, the most recent figure standing at 181.09% for Q4 2025.
- In Q4 2025, Return on Capital Employed fell 8666.0% year-over-year to 181.09%; the TTM figure through Dec 2025 stood at 181.09% (down 8666.0% YoY), while the FY2025 annual figure was 113.58%, down 4967.0% from the prior year.
- Return on Capital Employed was 181.09% for Q4 2025 at Senti Biosciences Holdings, down from 136.48% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 16.23% in Q4 2021 to a low of 181.09% in Q4 2025.
- Historically, Return on Capital Employed has averaged 74.09% across 5 years, with a median of 76.82% in 2025.
- Biggest YoY gain for Return on Capital Employed was 1611 bps in 2025; the steepest drop was 8666 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 16.23% in 2021, then tumbled by 140 bps to 38.95% in 2022, then plunged by 111 bps to 82.09% in 2023, then retreated by 15 bps to 94.44% in 2024, then slumped by 92 bps to 181.09% in 2025.
- The last three Return on Capital Employed figures came in at 181.09% (Q4 2025), 136.48% (Q3 2025), and 98.33% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -107.40% |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -50.43% |
| 10 | Senti Biosciences Holdings | 21.76 Mn | 21.76 Mn | - | -181.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -181.09% |
| Sep 30, 2025 | -136.48% |
| Jun 30, 2025 | -98.33% |
| Mar 31, 2025 | -76.82% |
| Dec 31, 2024 | -94.44% |
| Sep 30, 2024 | -100.50% |
| Jun 30, 2024 | -107.90% |
| Mar 31, 2024 | -92.92% |
| Dec 31, 2023 | -82.09% |
| Sep 30, 2023 | -71.19% |
| Jun 30, 2023 | -43.42% |
| Mar 31, 2023 | -43.15% |
| Dec 31, 2022 | -38.95% |
| Sep 30, 2022 | -28.96% |
| Jun 30, 2022 | -24.55% |
| Mar 31, 2022 | -22.56% |
| Dec 31, 2021 | -16.23% |